Skip to main content

Table 1 Patient characteristics

From: Fractionated stereotactic radiation therapy improves cranial neuropathies in patients with skull base meningiomas: a retrospective cohort study

Variable n Percent
Median Age (years) 60.7 (range 21–92)
Median Tumor Volume (cc) 8.7 (range 0.67 – 62.2)
Gender:
  Male 58 25.9%
  Female 166 74.1%
Location:
  Cavernous sinus 66 29.5%
  Parasellar 9 4.0%
  Sphenoid/clinoid 65 29.0%
  CPA 32 14.3%
  Clivus 7 3.1%
  Sellar/suprasellar 16 7.1%
  Planum 15 6.7%
  Craniocervical 13 5.8%
  Other 1 0.4%
Laterality
  Left 95 42.4%
  Right 84 37.5%
  Midline/Bilateral 44 19.6%
  Unknown 1 0.4%
Symptoms at time of Radiation
  Symptomatic 205 91.5%
  Asymptomatic 19 8.6%
Intensity Modulate Radiation Therapy
  Yes 41 18.3%
  No 183 81.7%
  Neurofibramatosis-2 3 1.4%
Treatment Group*:
  Radiation only 115 51.3%
  Adjuvant radiation 40 17.9%
  Progression after surgery 58 25.9%
  Re-irradiation 11 4.9%
Pathology
  No pathologic diagnosis 112 50.0%
  WHO grade I 108 48.2%
  WHO grade II 4 1.8%
Dose
  > 52.5 Gy 125 55.8%
  <= 52.2 Gy 99 44.2%
  1. * Per treatment course. Seven patients in the radiation only, adjuvant radiation or progression after surgery groups are also present in the re-irradiation group because they underwent a second course of fractionated stereotactic radiation therapy.